Skip to main content
. Author manuscript; available in PMC: 2010 Nov 23.
Published in final edited form as: Vaccine. 2009 Sep 26;27(50):7087–7095. doi: 10.1016/j.vaccine.2009.09.059

Table 2.

HIV-derived HTL epitopes used in vaccine design and synthesis

Protein Designation1 Amino Acid Sequence HLA-DR Antigens Bound
Env 566 IKQFINMWQEVGKAMY 8
Env 729 QHLLQLTVWGIKQLQ 9
Gag1712 QGQMVHQAISPRTLN 9
Gag 2942 GEIYKRWIILGLNKI 10
Gag 2982 KRWIILGLNKIVRMY 13
Pol 3032 FRKYTAFTIPSINNE 7
Pol 3352 SPAIFQSSMTKILEP 9
Pol 596 WEFVNTPPLVKLWYQ 11
Pol 7112 EKVYLAWVPAHKGIG 10
Pol 7122 KVYLAWVPAHKGIGG 10
Pol 758 HSNWRAMASDFNLPP 8
Pol 9152 KTAVQMAVFIHNFKR 8
Pol 9562 QKQITKIQNFRVYYR 12
Pol 6192 AETFYVDGAANRETK 2
Pol 674 EVNIVTDSQYALGII 3
Pol 874 WAGIKQEFGIPYNPQ 5
Pol 989 GAVVIQDNSDIKVVP 5
Vpu 312 YRKILRQRKIDRLID 7
1

Epitopes are designed based on their location within HIV viral gene products as noted in Table 1.

2

Immunogenicity of the individual peptides was established by immunizing H2bxd mice with peptide emulsified in CFA and measured as a function of peptide-specific IFN-γ production using an EPISPOT. Those indicated were immunogenic in mice and used for immunization controls and assays.